CA2346670A1 - Composition for the parenteral administration of active compounds - Google Patents

Composition for the parenteral administration of active compounds Download PDF

Info

Publication number
CA2346670A1
CA2346670A1 CA002346670A CA2346670A CA2346670A1 CA 2346670 A1 CA2346670 A1 CA 2346670A1 CA 002346670 A CA002346670 A CA 002346670A CA 2346670 A CA2346670 A CA 2346670A CA 2346670 A1 CA2346670 A1 CA 2346670A1
Authority
CA
Canada
Prior art keywords
composition
active compound
microparticles
water
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002346670A
Other languages
English (en)
French (fr)
Inventor
Jurgen Grande
Silke Schuth
Gitte Bohm
Holger Bengs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Celanese GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celanese GmbH filed Critical Celanese GmbH
Publication of CA2346670A1 publication Critical patent/CA2346670A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002346670A 1998-10-15 1999-10-02 Composition for the parenteral administration of active compounds Abandoned CA2346670A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1998147593 DE19847593A1 (de) 1998-10-15 1998-10-15 Zusammensetzung für die parenterale Applikation von Wirkstoffen
DE19847593.4 1998-10-15
PCT/EP1999/007300 WO2000021505A2 (de) 1998-10-15 1999-10-02 Zusammensetzung für die parenterale applikation von wirkstoffen

Publications (1)

Publication Number Publication Date
CA2346670A1 true CA2346670A1 (en) 2000-04-20

Family

ID=7884587

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002346670A Abandoned CA2346670A1 (en) 1998-10-15 1999-10-02 Composition for the parenteral administration of active compounds

Country Status (8)

Country Link
EP (1) EP1124538A2 (de)
JP (1) JP2002527376A (de)
AU (1) AU6198999A (de)
CA (1) CA2346670A1 (de)
DE (1) DE19847593A1 (de)
NO (1) NO20011670L (de)
PL (1) PL347770A1 (de)
WO (1) WO2000021505A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022095B4 (de) * 2000-05-08 2005-07-14 Südzucker AG Mannheim/Ochsenfurt Gel aus einem Poly-α-1,4-Glucan und Stärke
DE10119522A1 (de) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel
PL1711058T3 (pl) 2004-01-23 2022-02-07 Eden Research Plc Sposoby zabijania nicieni obejmujące aplikację składnika terpenowego
PT2338332E (pt) 2004-05-20 2014-05-15 Eden Research Plc Partícula oca de glucano ou partícula de parede celular que encapsula um componente de terpeno
WO2008106571A2 (en) 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2646879A1 (de) * 1975-10-21 1977-05-05 Takeda Chemical Industries Ltd Matrix aus einem in wasser unloeslichen beta-1,3-glucangel und verfahren zu ihrer herstellung
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
AU699552B2 (en) * 1994-05-18 1998-12-10 Bayer Cropscience Aktiengesellschaft DNA sequences coding for enzymes capable of facilitating the synthesis of linear alpha-1,4 glucans in plants, fungi and microorganisms
DE19737481A1 (de) * 1997-08-28 1999-03-04 Hoechst Ag Sphärische lineare Polysaccharide enthaltende Mikropartikel
ATE270097T1 (de) * 1998-04-09 2004-07-15 Celanese Ventures Gmbh Partikulärer wirkstoffträger für die pulmonale applikation
DE19839216C1 (de) * 1998-08-28 2000-01-20 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von sphärischen Mikropartikeln, die ganz oder teilweise aus mindestens einem wasserunlöslichen Verzweigungen enthaltenden Polyglucan bestehen, sowie mit diesem Verfahren erhältliche Mikropartikel und die Verwendung

Also Published As

Publication number Publication date
NO20011670L (no) 2001-06-12
PL347770A1 (en) 2002-04-22
WO2000021505A2 (de) 2000-04-20
WO2000021505A3 (de) 2000-09-21
NO20011670D0 (no) 2001-04-03
EP1124538A2 (de) 2001-08-22
DE19847593A1 (de) 2000-04-20
JP2002527376A (ja) 2002-08-27
AU6198999A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
Mitra et al. Chitosan microspheres in novel drug delivery systems
Varshosaz et al. Nasal delivery of insulin using chitosan microspheres
EP1906928B1 (de) Kerne und mikrokapseln für die parenterale verabreichung und herstellungsverfahren dafür
Agnihotri et al. Recent advances on chitosan-based micro-and nanoparticles in drug delivery
JP4537057B2 (ja) 脂質化グリコサミノグリカン粒子ならびに診断及び処置のための薬物及び遺伝子送達におけるその使用
JP3094074B2 (ja) 多糖ゲル組成物
TWI314461B (en) Amphiphilic block copolymers and nano particles comprising the same
EP1891941A1 (de) Wässrige Gele enthaltend Mikrokügelchen
WO1984000294A1 (en) A crystallised carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
CN101374530A (zh) 壳聚糖和肝素纳米微粒
Gupta et al. Optimization of process variables for the preparation of chitosan-alginate nanoparticles
CA2583341A1 (en) Method of formation of the shape-retentive aggregates of gel particles and their uses
Pal et al. Chitosan based delivery systems on a length scale: Nano to macro
EP1371364B1 (de) Verfahren zur Herstellung eines Systems mit gesteuerter Freisetzung
Mohammadpour et al. Preparing and characterizing chitosan nanoparticles containing hemiscorpius lepturus scorpion venom as an antigen delivery system
Lee et al. Stabilization of protein encapsulated in poly (lactide-co-glycolide) microspheres by novel viscous S/W/O/W method
Chauhan et al. Pharmaceutical polymers
US8017152B2 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
Priya Dasan et al. Polymer blend microspheres for controlled drug release: The techniques for preparation and characterization: A review article
AU2003205106A8 (en) Pace-a microspheres for delivery of antigens
CA2346670A1 (en) Composition for the parenteral administration of active compounds
Portilla‐Arias et al. Biodegradable Nanoparticles of Partially Methylated Fungal Poly (β‐l‐malic acid) as a Novel Protein Delivery Carrier
Chouhan et al. An updated review on nanoparticle based approach for nanogel drug delivery system
CN115337272B (zh) 一种天然多糖基化学-物理双交联水凝胶微粒及其制备与应用
Manna et al. Interpenetrating polymer network in microparticulate systems: drug delivery and biomedical application

Legal Events

Date Code Title Description
FZDE Discontinued